Drug intelligence / Profile preview

LYB005

Development stage: Phase 2
Lead developer: Guangzhou Patronus Biotech
Modality: Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

LYB005 is a virus-like particle vaccine developed by Guangzhou Patronus Biotech, a subsidiary of Luye Life Sciences Group, for the prevention of respiratory syncytial virus (RSV) infections. It is designed as a prophylactic vaccine and functions as an immunostimulant to elicit an immune response against RSV. The vaccine is currently in preclinical and early clinical development stages, with phase 1 trials planned or ongoing in China and Australia for the prevention of RSV infections[1][2][3][7][8].

Other names: Recombinant Respiratory Syncytial Virus Vaccine Guangzhou Patronus Biotech

Beyond the preview

Go deeper on LYB005.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LYB005.

Explore the full profile